• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人胎盘核糖核酸酶抑制剂。纯化及性质

Ribonuclease inhibitor from human placenta. Purification and properties.

作者信息

Blackburn P, Wilson G, Moore S

出版信息

J Biol Chem. 1977 Aug 25;252(16):5904-10.

PMID:560377
Abstract

A soluble ribonuclease inhibitor from the human placenta has been purified 4000-fold by a combination of ion exchange and affinity chromatography. The inhibitor has been isolated in 45% yield (about 2 mg/placenta) as a protein that is homogeneous by sodium dodecyl sulfate-gel electrophoresis. In common with the inhibitors of pancreatic ribonuclease from other tissues that have been studied earlier, the placental inhibitor is an acidic protein of molecular weight near 50,000; it forms a 1:1 complex with bovine pancreatic RNase A and is a noncompetitive inhibitor of the pancreatic enzyme, with a Ki of 3 X 10(-10) M. The amino acid composition of the protein has been determined. The protein contains 30 half-cystine plus cysteine residues determined as cysteic acid after performic acid oxidation. At pH 8.6 the nondenatured protein alkylated with iodoacetic acid in the presence of free thiol has 8 free sulfhydryl groups. The inhibitor is irreversibly inactivated by sulfhydryl reagents and also by removal of free thiol from solutions of the protein. Inactivation by sulfhydryl reagents causes the dissociation of the RNase - inhibitor complex into active RNase and inactive inhibitor.

摘要

通过离子交换和亲和层析相结合的方法,从人胎盘中纯化出一种可溶性核糖核酸酶抑制剂,纯化倍数达4000倍。该抑制剂的分离产率为45%(约2毫克/胎盘),通过十二烷基硫酸钠 - 凝胶电泳检测为单一蛋白质。与之前研究过的其他组织来源的胰腺核糖核酸酶抑制剂一样,胎盘抑制剂是一种分子量接近50,000的酸性蛋白质;它与牛胰腺核糖核酸酶A形成1:1复合物,是该胰腺酶的非竞争性抑制剂,抑制常数Ki为3×10(-10)M。已测定该蛋白质的氨基酸组成。该蛋白质含有30个半胱氨酸加半胱氨酸残基,在过甲酸氧化后测定为半胱氨酸。在pH 8.6时,在游离巯基存在下用碘乙酸烷基化的未变性蛋白质有8个游离巯基。该抑制剂可被巯基试剂不可逆地灭活,也可通过从蛋白质溶液中去除游离巯基而灭活。巯基试剂导致核糖核酸酶 - 抑制剂复合物解离成活性核糖核酸酶和无活性抑制剂。

相似文献

1
Ribonuclease inhibitor from human placenta. Purification and properties.人胎盘核糖核酸酶抑制剂。纯化及性质
J Biol Chem. 1977 Aug 25;252(16):5904-10.
2
Interaction of human placental ribonuclease with placental ribonuclease inhibitor.人胎盘核糖核酸酶与胎盘核糖核酸酶抑制剂的相互作用
Biochemistry. 1991 Feb 26;30(8):2246-55. doi: 10.1021/bi00222a030.
3
Ribonuclease inhibitor from bovine brain.来自牛脑的核糖核酸酶抑制剂。
Int J Pept Protein Res. 1980 Nov;16(5):359-64. doi: 10.1111/j.1399-3011.1980.tb02959.x.
4
Ribonuclease inhibitor from pig brain: purification, characterization, and direct spectrophotometric assay.猪脑核糖核酸酶抑制剂:纯化、特性鉴定及直接分光光度法测定
Anal Biochem. 1989 Jan;176(1):175-9. doi: 10.1016/0003-2697(89)90289-3.
5
Ribonuclease inhibitors from the livers of five mammalian species.来自五种哺乳动物肝脏的核糖核酸酶抑制剂。
Int J Pept Protein Res. 1982 Apr;19(4):372-9. doi: 10.1111/j.1399-3011.1982.tb02618.x.
6
Studies on the interaction of ribonuclease inhibitor with pancreatic ribonuclease involving differential labeling of cysteinyl residues.关于核糖核酸酶抑制剂与胰腺核糖核酸酶相互作用的研究,涉及半胱氨酸残基的差异标记。
J Biol Chem. 1991 Dec 15;266(35):24198-204.
7
Purification and characterization of human pancreatic ribonuclease.人胰腺核糖核酸酶的纯化与特性分析
Biochemistry. 1981 Mar 3;20(5):1272-8. doi: 10.1021/bi00508a035.
8
Identification of lysine residues in the binding domain of ribonuclease A for the RNase inhibitor from human placenta.核糖核酸酶A与来自人胎盘的核糖核酸酶抑制剂结合结构域中赖氨酸残基的鉴定。
J Biol Chem. 1982 Jan 10;257(1):316-21.
9
Purification of mammalian ribonuclease using immobilized human ribonuclease inhibitor.使用固定化人核糖核酸酶抑制剂纯化哺乳动物核糖核酸酶
Protein Expr Purif. 1996 Mar;7(2):167-72. doi: 10.1006/prep.1996.0024.
10
Isolation and characterization of sulfhydryl oxidase from bovine milk.牛乳中巯基氧化酶的分离与鉴定
J Biol Chem. 1975 Apr 10;250(7):2532-8.

引用本文的文献

1
Staphylococcus aureus utilizes environmental RNA as a building material in specific polysaccharide-dependent biofilms.金黄色葡萄球菌利用环境 RNA 作为特定多糖依赖性生物膜的建筑材料。
NPJ Biofilms Microbiomes. 2022 Apr 4;8(1):17. doi: 10.1038/s41522-022-00278-z.
2
Robust Recombinant Expression of Human Placental Ribonuclease Inhibitor in Insect Cells.昆虫细胞中稳定的重组人胎盘核糖核酸酶抑制剂表达。
Biomolecules. 2022 Feb 8;12(2):273. doi: 10.3390/biom12020273.
3
Improving the Repeatability and Efficacy of Intradermal Electroporated Self-Replicating mRNA.
提高皮内电穿孔自我复制信使核糖核酸的重复性和疗效。
Mol Ther Nucleic Acids. 2019 Sep 6;17:388-395. doi: 10.1016/j.omtn.2019.06.011. Epub 2019 Jun 28.
4
Angiogenin Mediates Cell-Autonomous Translational Control under Endoplasmic Reticulum Stress and Attenuates Kidney Injury.血管生成素在内质网应激下介导细胞自主翻译控制并减轻肾损伤。
J Am Soc Nephrol. 2016 Mar;27(3):863-76. doi: 10.1681/ASN.2015020196. Epub 2015 Jul 20.
5
The aggregation states of spinach phosphoribulokinase.菠菜磷酸核糖激酶的聚集态。
Planta. 1990 Jun;181(3):349-57. doi: 10.1007/BF00195887.
6
An endogenous ribonuclease inhibitor regulates the antimicrobial activity of ribonuclease 7 in the human urinary tract.一种内源性核糖核酸酶抑制剂调节人泌尿道中核糖核酸酶7的抗菌活性。
Kidney Int. 2014 May;85(5):1179-91. doi: 10.1038/ki.2013.395. Epub 2013 Oct 9.
7
Ribonuclease/angiogenin inhibitor 1 regulates stress-induced subcellular localization of angiogenin to control growth and survival.核糖核酸酶/血管生成素抑制剂1调节应激诱导的血管生成素亚细胞定位以控制生长和存活。
J Cell Sci. 2013 Sep 15;126(Pt 18):4308-19. doi: 10.1242/jcs.134551. Epub 2013 Jul 10.
8
Heterologous production of active ribonuclease inhibitor in Escherichia coli by redox state control and chaperonin coexpression.通过氧化还原状态控制和伴侣蛋白共表达在大肠杆菌中异源生产活性核糖核酸酶抑制剂。
Microb Cell Fact. 2011 Aug 8;10:65. doi: 10.1186/1475-2859-10-65.
9
Reducing conditions are the key for efficient production of active ribonuclease inhibitor in Escherichia coli.降低条件是大肠杆菌中高效生产活性核糖核酸酶抑制剂的关键。
Microb Cell Fact. 2011 May 10;10:31. doi: 10.1186/1475-2859-10-31.
10
Novel approach of high cell density recombinant bioprocess development: optimisation and scale-up from microliter to pilot scales while maintaining the fed-batch cultivation mode of E. coli cultures.新型高密度细胞重组生物工艺开发方法:在保持大肠杆菌补料分批培养模式的同时,从微升到中试规模进行优化和放大。
Microb Cell Fact. 2010 May 20;9:35. doi: 10.1186/1475-2859-9-35.